BN Business News
Add your company to Business Communicator →

Business · 03/07/2025

Prospective Grant of an Exclusive Patent License: The Development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for the Treatment or Prevention of B Cell Mediated Autoimmune Diseases

The National Cancer Institute is contemplating an Exclusive Patent License grant to Capstan Therapeutics, Inc. for the development of an in vivo Anti-CD19 Chimeric Antigen Receptor (CAR) for treating or preventing B Cell Mediated Autoimmune Diseases.

Original source language: Federal Register — Health and Human ServicesOpen original release →

Explore insights